Presentación    
GROUP 20.
INNATE IMMUNE RESPONSE
Composition
Name
Position
Institution
Eduardo Manuel López Collazo
Investigador. Jefe de Laboratorio
Hospital Universitario La Paz
Susana Alemany de La Peña
Investigador. Jefe de Laboratorio
IIB Alberto Sols. CSIC-UAM
Lisardo Boscá Gomar
Investigador. Jefe de Laboratorio
IIB Alberto Sols. CSIC-UAM
Antonio Castrillo Viguera
Investigador. Jefe de Laboratorio
IIB Alberto Sols. CSIC-UAM
Irene Fernández Ruiz
Investigadora Predoctoral
Hospital Universitario La Paz
María Susana Guerra García
Investigadora Postdoctoral
Universidad Autónoma de Madrid
Teresa Jurado Camino
Investigadora Predoctoral
Hospital Universitario La Paz
Paloma Martín Sanz
Investigador. Jefe de Laboratorio
IIB Alberto Sols. CSIC-UAM
María Fernández Velasco 
Investigadora Posdoctoral 
IIB. Alberto Sols. CSIC-UAM
Summary
This group focuses on the study of the reprogramming of the innate immune response in the context of inflammatory diseases (e.g., sepsis, cystic fibrosis, acute coronary
syndrome, lung cancer) using the description of the various molecular mechanisms that underlie the reprogramming of monocytes/macrophages during refractory states.
The innate immune response is activated in various clinical contexts that can be modelled in vitro. The initial reaction of the Innate Immune System is marked by an
inflammatory response that is similar in different contexts.
However, after the initial response, a “deviation” is produced towards an “alternative” response that may, in many cases, lead to refractory states such as endotoxin and tumour tolerance. These refractory states may have undesirable clinical consequences and their study is the objective of our research.
Lines of research
• Molecular mechanisms of endotoxin tolerance in several clinical contexts: respiratory diseases (COPD and cystic fibrosis), acute coronary syndrome, sepsis and septic shock.
• Role of microRNAs in the activation of states refractory to endotoxins and tumours.
• Role of TREM-1 as a marker of lung diseases.
• Molecular mechanisms of the innate immune system tolerance to tumours.
• Role of IRAK-M pseudokinase and TREM-1 receptor in endotoxin tolerance in various clinical contexts.